3 Search Results

q=Computational%20Biology

Search Again


Amy Paguirigan , PhD

Email: apaguiri@fredhutch.org

Phone: (206) 667-4352

The focus of my research has been the integration of emerging technologies to address clinically relevant questions in cancer biology. My focus is on the interface between clinical molecular biology, bioinformatics and biotechnology, in aiming to bridge the gaps to bring novel approaches in both the biotechnological and informatics realms to clinical molecular biology to study the role of clonal diversity in cancer therapy.

View Bio

Takuma Uo , Ph.D.

Email: tuo@uw.edu

Phone: 206-897-5463

Age is the most common risk factor for prostate cancer, with the rapid rise in its incidence after age 50. As a member of the prostate cancer research group in Division of Gerontology and Geriatric Medicine, Dr. Uo is focused on understanding molecular logics behind adaptive resistance of prostate cancer cells to the most forefront androgen-targeted therapies. Specifically, his research program examines the cell autonomous and nonautonomous mechanisms that enable prostate cancer progression, including the constitutively-active isoforms of androgen receptor, the metabolic rewiring, and the extracellular fuel supply from tumor microenvironment and adipose tissues. He harnesses in-depth knowledge and advanced technologies of molecular, cellular, chemical, synthetic, and computational biology to help develop next-generation of therapeutics to improve patient survival.

View Bio

Wei Wei , PhD

Email: wwei@systemsbiology.org

Phone: (206) 732-1221

The Wei group works in the highly cross-disciplinary field of BioMEMS, molecular and cellular analysis, and systems biomedicine. These joint efforts allow us to integrate single cell technologies with other biotechnological tools and computational approaches to investigate cutting-edge cancer biology questions with a balance between discovery and clinical translation. Specifically, we are interested in the following three areas: 1) Single-cell multi-omics tools and associated multivariate computational approaches for interrogating the heterogeneous tumor cells and immune cells at multiple bimolecular levels; 2) Epigenetic remodeling and signaling network dynamics associated with cell state transition and resistance development in epigenetically plastic tumors; 3) Liquid biopsy-based rare cell analysis for cancer metastasis and immunotherapy.

View Bio